Novo Tellus Alpha Acquisition (NOVO)

Currency in SGD
5.14
0.00(0.00%)
Closed·

NOVO Earnings

Latest Release
Aug 08, 2023
EPS / Forecast
0.01 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
06/20230.01/----/------Free Sign Up
12/20220.3/----/------Free Sign Up
06/20220.12/----/------Free Sign Up

All numbers in SGD

Novo Tellus Alpha Acquisition Earnings Call Summary for Q2/2025

  • Novo Nordisk reports 18% revenue growth and 29% operating profit increase in H1 2024, revises full-year sales growth guidance to 8-14%
  • Company plans U.S. launch of oral semaglutide for obesity by early 2026, expands patient base to 45 million globally
  • Free cash flow of DKK 34 billion fully returned to shareholders; company maintains 71% volume market share in key markets
  • Anticipates low single-digit top-line impact from loss of exclusivity in 2026, focuses on product pipeline and market expansion
  • Faces challenges in U.S. obesity market competition, slowing GLP-1 diabetes market growth, and compounding market estimated at 30%
Last Updated: 18/08/2025, 23:04
Read Full Transcript
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.